MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on ANI Pharmaceuticals, with a price target of $124.00. The company’s shares closed yesterday at $72.17. Divan ...
ASX healthcare stocks remain under pressure, but strong clinical and regulatory catalysts are still driving standout gains across the sector. ... Read More The post Scott Power: Conflict, inflation ...
Investor's Business Daily on MSN
Two biotech stocks hover near highs; natural gas and finance names show resilience
Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.
Zacks Small Cap Research on MSN
CING: Laying the foundation for 1H:27 launch
By John Vandermosten, CFA NASDAQ: CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported 2025 ...
Dan Yoo took a breath before describing what he saw when he stopped into work on a Sunday morning at the Larry C. Hardy ...
Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of ...
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results